Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.

Pharmacology & therapeutics - 1 Jun 2017

Lee Dae Ho

Abstract excerpt

The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) have changed the paradigm of cancer therapy from empirical cytotoxic chemotherapy to molecular-targeted cancer therapy. As a result, EGFR TKI therapy, including gefitinib, erlotinib and afatinib, has become the standard therapy for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 28167215
DOI: 10.1016/j.pharmthera.2017.02.001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.PMID 28167215Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.Semantic proximity Read ↗

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.Semantic proximity Read ↗

[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer.Semantic proximity Read ↗

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.Semantic proximity Read ↗

EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)Semantic proximity Read ↗

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.Semantic proximity Read ↗

Emerging treatment for advanced lung cancer with EGFR mutation.Semantic proximity Read ↗

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Semantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.